Hans Biomed

Hans Biomed EBIT per Share

The EBIT per Share of Hans Biomed (042520.KQ) as of Nov 1, 2026 is 48.51 KRW. In the previous year, EBIT per Share was -390.53 KRW — a change of -112.42% (higher).

EBIT per Share

48.51KRW

YoY

-112.42%

Last updated:

EBIT per Share of Hans Biomed is 2024 48.51 KRW. EBIT per Share of Hans Biomed was 2023 -390.53 KRW. It decreases by -112.42% higher compared to the previous year.

The Hans Biomed EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
1,111.09 KRW
Jan 1, 2020
-340.29 KRW
Jan 1, 2021
-1,632.42 KRW
Jan 1, 2022
130.25 KRW
Jan 1, 2023
-390.53 KRW
Jan 1, 2024
48.51 KRW
Jan 1, 2026 (e)
699.93 KRW
Jan 1, 2027 (e)
0.00 KRW
The Hans Biomed EBIT per Share history
YEAREBIT per ShareYoY
est0.00KRW-100.00%
est699.93KRW+1,342.86%
48.51KRW-112.42%
-390.53KRW-399.83%
130.25KRW-107.98%
-1,632.42KRW+379.72%
-340.29KRW-130.63%
1,111.09KRW+81.40%
612.51KRW-37.62%
981.83KRW+57.12%
624.89KRW-13.52%
722.58KRW+29.53%
557.84KRW+0.27%
556.33KRW+23.67%
449.86KRW+473.59%
78.43KRW-24.95%
104.50KRW-65.33%
301.43KRW+6.73%
282.43KRW+44.73%
195.14KRW+30.47%
149.57KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hans Biomed Stock analysis

What does Hans Biomed do? Hans Biomed Corp manufactures and sells graft material and silicon products under brand names SureDerm, BellaGen, and GPS for skin-implant materials used in burn treatment and skin graft. The company offers bone-implant materials including allogeneic bones, xenogenous bones, and synthetic bones under SureFuse, ExFuse, and SureOss for dentistry and orthopedic applications. Silicone products such as BellaGel and Scar Clinic are utilized for scar treatment and breast implants. The firm also provides hair transplanters as part of its product portfolio. Skin-implant materials under SureDerm, BellaGen, and GPS are purchased by medical facilities for burn treatment and skin graft procedures. Bone-implant materials under SureFuse, ExFuse, and SureOss are bought by dental and orthopedic clinics for various surgical needs. Silicone products BellaGel and Scar Clinic are acquired by healthcare providers for scar management and breast implant surgeries. Hair transplanters are sold to medical institutions requiring such equipment. The company's primary revenue streams come from the sale of skin-implant materials, bone-implant materials, and silicone products across medical, dental, and orthopedic sectors. Medical facilities, dental clinics, and orthopedic practices represent key customer segments. Brand names SureDerm, BellaGen, GPS, SureFuse, ExFuse, SureOss, BellaGel, and Scar Clinic drive product differentiation and market positioning in the healthcare industry. Hans Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hans Biomed stock

EBIT per Share of Hans Biomed is 48.51 KRW in 2024.

EBIT per Share of Hans Biomed changed from -390.53 KRW to 48.51 KRW, representing a -112.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Hans Biomed since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Hans Biomed

All Key Metrics — Hans Biomed